OncoMatch/Clinical Trials/NCT06049667
A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies
Is NCT06049667 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies NTQ2494 tablet for relapsed/refractory acute myeloid leukemia (aml).
Treatment: NTQ2494 tablet — NTQ2494 tablet, an anti-tumor molecular targeted drug, is an AXL kinase inhibitor. The objectives were to evaluate the safety and tolerability, PK characteristics and preliminary efficacy of NTQ2494 tablets in patients with advanced hematological malignancies.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: anticancer therapy
Receiving anticancer therapy including immunotherapy, targeted therapy, endocrine therapy, radiotherapy and chemotherapy within 2 weeks or 5 half-lives (whichever is longer) prior to starting study treatment
Cannot have received: investigational agent
Receiving any other investigational agents within 4 weeks prior to starting study treatment
Cannot have received: allogeneic hematopoietic stem cell transplantation
Patients who have received previous allogeneic hematopoietic stem cell transplantation
Cannot have received: autologous hematopoietic stem cell transplantation
Exception: within 3 months prior to starting study treatment
received autologous hematopoietic stem cell transplantation within 3 months prior to starting study treatment
Lab requirements
Blood counts
adequate bone marrow
Kidney function
good organ function
Liver function
good organ function
Adequate bone marrow and good organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify